KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Weighted Average): 2017-2025

Historic Shares Outstanding (Weighted Average) for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $99.7 million.

  • Aquestive Therapeutics' Shares Outstanding (Weighted Average) rose 9.51% to $99.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.7 million, marking a year-over-year increase of 9.51%. This contributed to the annual value of $91.2 million for FY2024, which is 36.56% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Shares Outstanding (Weighted Average) is $99.7 million, which was up 0.40% from $99.3 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $99.7 million for Q3 2025, and its period low was $36.2 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $80.4 million, with a median of $91.0 million in 2024.
  • Data for Aquestive Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 62.79% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Shares Outstanding (Weighted Average) stood at $40.2 million in 2021, then spiked by 34.84% to $54.2 million in 2022, then rose by 23.29% to $66.8 million in 2023, then surged by 36.56% to $91.2 million in 2024, then increased by 9.51% to $99.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $99.7 million in Q3 2025, compared to $99.3 million in Q2 2025 and $98.9 million in Q1 2025.